1/1/0001 - Posted in  Pharmaceutical Affairs

AbbVie saves its skin by buying Allergan

Our expert's opinion

AbbVie will no longer have a monopoly on Humiria, a treatment that brought them 60% of their turnover. To face this, AbbVie has turned to Botox produced by Allergan because this product doesn’t use any Brevet. The merger of these two companies is expected to generate $19 billion, which would repay the debt and also exploit existing materials to create new products.

Impressive rebound. The American company was able to anticipate the flaws and rebounded with a “bold” solution. What do you think about it?

- Nora Jamai, Associate Consultant

Other insights in Pharmaceutical Affairs